Rho

Are your teams aligned to respond when timelines accelerate? In acute pain trials, they have to be. In one study, when enrollment happened faster than expected, pressure built quickly downstream. What mattered most was how our team responded—shifting seamlessly in real time to resolve the issue early, protect data, and keep timelines on track. See how cohesion drives execution in acute pain trials: https://lnkd.in/e7TzvfQr

We’ll see you at the 7th World Parkinson Congress in Phoenix! For us, this one is different. That’s because it’s one of the few places where the full Parkinson’s community can show up together to talk about what’s working, what’s not, and what’s next for PD research. Our team will be there and ready to discuss what strong execution looks like in Parkinson’s disease trials. It’s work grounded both in science and the people behind it. If you’re interested in hearing how cohesive teams deliver, let us know: https://lnkd.in/emK3-6YZ

Last week, Marta Bogusławska joined a fantastic panel discussion at the Society for Clinical Data Management (SCDM) 2026 EMEA Conference about driving the change from clinical data management to clinical data science. Alongside fellow panelists, she shared perspectives on where the industry stands in this transition, and how we need to rethink what value truly means in data management. By shifting our focus from the volume of outputs to their impact, we can reduce burden for sites, support better decision-making, and ultimately improve outcomes for patients. We’re proud to be a part of these conversations as they reinforce what our team at Rho practices in our work every day: Data management can be efficient and still deliver meaningful benefits for everyone involved. 

May is Huntington’s Disease Awareness Month! This month, we’re proud to support HD awareness and advocate for the thousands of families impacted by this genetic neurodegenerative disease. Through our work with our partners and advocacy organizations, we are committed to running smarter, more compassionate clinical trials that make a real difference for patients and their loved ones—while keeping them at the center of everything we do. Together, we hope—and are working toward—a day when there is a cure for HD. #LetsTalkAboutHD

#ICYMI One of our latest insights blogs breaks down how late-stage regulatory surprises rarely come from one big mistake. Usually, they trace back to early decisions that seemed perfectly reasonable in the moment but were made without full downstream context. Viewing choices through a regulatory lens earlier (and more often) can help keep your program on track—without slowing development: https://lnkd.in/ey_QBp4V

In your trial development, do you ever catch yourself thinking, “We can always adjust this later”? Early on, that mindset feels reasonable. But behind the scenes, regulators are already forming a view of what your program is meant to prove. Here’s why early decisions quietly shape your approval story—and how the Cohesion Effect helps reduce friction over time: https://lnkd.in/ePXectMg

We're excited to join Nexus Conference for the 26th BioPharma Clinical Trials Nexus next week! Kiley Boggs will be in Philadelphia to engage in meaningful conversations and explore opportunities for us to shape the future of clinical research—together. If you’re looking to tackle your next trial with confidence, let’s chat. Our capabilities extend across the clinical development lifecycle, helping teams execute seamlessly to drive better outcomes. Learn more about how we use our collective intelligence in practice, and where you can find Rho on the road throughout the year: https://lnkd.in/emK3-6YZ

Is your acute pain study set up to behave the way it’s designed to? On paper, most will say yes…but then the study meets real life. As enrollment accelerates, populations diversify, and clinical realities take hold, even small shifts can influence how clearly treatment benefit can be demonstrated. A design that seems well-controlled early on can become much harder to interpret once these dynamics start building. This short field guide breaks down three inflection points we’re seeing repeatedly in acute pain studies today—and the early warning signs to watch for. If you’re working in acute pain, this is the kind of early awareness that pays off. Strengthen your acute pain study from the start: https://lnkd.in/eqESsQJ5

Acute pain trials don’t wait—they operate at a pace unlike others. Rho doesn’t respond to this in a panic…we just act. We understand there’s a narrow window for impact. Rather than waiting to respond at the first sign of stress, we align the right people at the right time to protect the data and scientific moment. Our collective intelligence is a strength, but it’s our coordinated execution that makes us different and gets you the results you set out for. Check out our approach to acute pain trials and why it works: https://lnkd.in/e7TzvfQr

Rho has had a great first day at #CMOSummit360! Andrew Feigin, Demis N. Lipe, MD, MS, and Todd Watters are at Booth #42 through tomorrow, sharing how Rho is a different kind of CRO built around connection. If you’re at the event, stop by to hear how we build lasting relationships, love science, and embrace the process—just like you. From early clinical program strategy through regulatory approval, we work alongside your team to bring breakthrough treatments to market. Learn more about how we work: https://lnkd.in/e9EBmsmu